Open to all ACG 2023 attendees, industry-sponsored satellite symposia provide additional educational opportunities for attendees. These programs are independent of the ACG 2023 Annual Scientific Meeting & Postgraduate Course programs. ACG is not the continuing medical education provider of these programs. For more information, see the company sponsor.
Monday, October 23
Managing Recurrent Clostridioides Difficile Infection: Advancing the Science of Microbiome-Based Therapies
Paul Feuerstadt, MD, FACG; Teena Chopra, MD, MPH; Anne J. Gonzales-Luna, PharmD, BCIDP
5:30 am – 7:30 am • Vancouver Convention Centre East, East Ballroom A
Join a panel of two expert clinicians as they discuss new and emerging microbiome-based therapies for preventing recurrent Clostridioides difficile infection and how these agents may substantially improve patient quality of life. Earn 1.5 AMA PRA Category 1 CreditTM or 1.5 Accreditation Council for Pharmacy Education (ACPE) contact hour. Complimentary breakfast provided! Visit the Gastroenterology & Endoscopy News exhibit booth, #1714, for more information.
This activity is supported by an educational grant from Ferring Pharmaceuticals, Inc.
Exclusive from Vancouver: A Spotlight on Ulcerative Colitis Experts
David T. Rubin, MD, FACG; Bruce E. Sands, MD, MS, FACG; Marla C. Dubinsky, MD
7:00 pm – 8:30 pm • Pinnacle Hotel, Cordova Ballroom
Join us for the unique opportunity to engage with experts as they share their personal insights on ulcerative colitis management. Dinner will be served from 7:00 pm.
This program is sponsored by Eli Lilly and Company
A New Era in the Management of Gastroesophageal Reflux Disease
7:30 pm – 8:45 pm • Fairmont Waterfront Hotel, Waterfront Ballroom C
Gastroesophageal reflux disease (GERD) is a highly prevalent, chronic gastrointestinal disorder that can result in serious complications if undertreated. Proton pump inhibitors (PPIs), the mainstay of GERD treatment, are generally safe and effective; however, some patients undergo PPI therapy for years but have recurrent or refractory symptoms. A new class of acid-suppressing therapies is in late-stage clinical development and nearing approval. In this live, interactive townhall, expert faculty will discuss the latest evidence regarding the diagnosis and management of GERD and erosive esophagitis (EE), including new medical therapies. Faculty will use patient cases to contextualize clinical information on GERD diagnosis and management that learners can apply in their own practices.
Supported by an independent educational grant from Phathom Pharmaceuticals.